Cargando…

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype

Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic asthma. However, the eligibility of biologics...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-Pérez, Ruperto, Poza-Guedes, Paloma, Mederos-Luis, Elena, Sánchez-Machín, Inmaculada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599709/ https://www.ncbi.nlm.nih.gov/pubmed/36289896 http://dx.doi.org/10.3390/biomedicines10102635

Ejemplares similares

Safety of a dust mite extract in severe allergic asthma
por: González-Pérez, Ruperto, et al.
Publicado: (2013)

Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: A real-world experience
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Storage Mite Precision Allergy Molecular Diagnosis in the Moderate-to-Severe T2-High Asthma Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Role of Predatory Mites in Persistent Nonoccupational Allergic Rhinitis
por: Poza Guedes, Paloma, et al.
Publicado: (2016)

Molecular Mapping of Allergen Exposome among Different Atopic Phenotypes
por: González-Pérez, Ruperto, et al.
Publicado: (2023)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Management of a Immunotherapy Unit During the COVID-19 Outbreak: Building a Resilient Health Care System.
por: Sanchez-Machin, Inmaculada, et al.
Publicado: (2021)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Role of specific IgE to β-lactoglobulin in the gastrointestinal phenotype of cow’s milk allergy
por: Poza-Guedes, Paloma, et al.
Publicado: (2016)

Immediate anaphylaxis after the ingestion of fig fruit (Ficus carica)
por: Gonzalez Perez, Ruperto, et al.
Publicado: (2015)

Oral cow’s milk immunotherapy: clinical and serological data in long-term follow up
por: Poza Guedes, Paloma, et al.
Publicado: (2015)

Cluster subcutaneous allergen immunotherapy as a sustainable practice towards net zero healthcare
por: Domínguez Estirado, Alicia, et al.
Publicado: (2023)

House Dust Mite Precision Allergy Molecular Diagnosis (PAMD@) in the Th2-prone Atopic Dermatitis Endotype
por: González-Pérez, Ruperto, et al.
Publicado: (2021)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

Accuracy in diagnosis of allergy to β-lactams
por: Iglesias-Souto, Javier, et al.
Publicado: (2012)

Evaluation of major mite allergens from European standardized commercial extracts for in vivo diagnosis: addressing the need for precision medicine
por: González-Pérez, Ruperto, et al.
Publicado: (2019)

A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals
por: Barrios, Yvelise, et al.
Publicado: (2021)

The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals
por: Barrios, Yvelise, et al.
Publicado: (2021)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
por: Matsumoto, Nobuhiro, et al.
Publicado: (2019)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
por: Karim, Azmat, et al.
Publicado: (2022)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Genomics of Treatable Traits in Asthma
por: Espuela-Ortiz, Antonio, et al.
Publicado: (2023)

Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‐to‐severe asthma
por: Chen, Meng, et al.
Publicado: (2021)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i49rkghpqvl47l8431eu313v2r